William Lubell

Université de Montréal

An originator of novel approaches for educating and performing research on medicinal chemistry in academia, Lubell has made seminal advances towards employing peptides in drug discovery. Innovating protocols for creating constrained amino acid and peptide surrogates to study structure-activity relationships, he developed the submonomer synthesis of azapeptides, aminolactam scanning and azabicycloalkane amino acid libraries for the rapid assessment of biologically relevant conformations and the evolution of peptide leads into peptidomimetic drug candidates with improved pharmacokinetic properties. Forging collaborations with biochemists, pharmacologists and physicians, his medicinal chemistry efforts have been key for teams developing intellectual property for drug discovery. For example, by developing allosteric modulators to regulate the prostaglangin-F2a receptor as interventions to prevent premature birth, an unmet-medical need with the highest cost per patient, he designed a novel lead soon to enter phase II clinical trials. Exploring peptidomimetic allosteric modulators of the interleukin-1 receptor, he developed candidates demonstrating efficacy in animal models of inflammatory bowel disease, psoriasis and osteoarthritis. Targeting the CD-36 scavenger receptor, he introduced lead molecules to treat age-related macular degeneration, the leading cause of adult blindness.